title: [Expression of FLI-1 and analysis of prognostic factors in primitive neuroectodermal tumor].
abstract: OBJECTIVE
  To observe the expression of FLI-1 in primitive neuroectodermal tumors (PNET), explore the value of immunohistochemical staining of FLI-1 in combination with other neural markers in diagnosis of PNET, and analyze the prognostic factors in PNET patients.
  
  
  METHODS
  35 cases of PNET, of which 33 cases with complete clinical data, were included in this study. Immmunohistochemistry (The En Vision method) was applied to detect the expression of FLI-1, CD99, Syn, NSE, S-100, NF, Vim in the tumor tissues. The clinicopathological data of 33 cases were analyzed by Cox regression.
  
  
  RESULTS
  The positive expression rate of FLI-1 were 51.4% and that of CD99 was 88.6%. The sensitivity of FLI-1 combined with CD99 was up to 100%. The positive rates of Vim, Syn, NSE, s-100 and NF were 91.4%, 48.6%, 45.7%, 22.9% and 0, respectively. Cox regression analysis showed that the impact of primary location and treatment modality were of statistical significance (P < 0.05), but the age, sex, stage or size of tumors did not (P > 0.05).
  
  
  CONCLUSIONS
  Immunohistochemical detection of FLI-1 and neural markers is a preferred method for clinical diagnosis of PNET. The main factors affecting the prognosis are the primary location of PNET and treatment modality.
authors.affiliation: Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Chen
authors.forename: Yong-Xu
authors.initials: YX
authors.lastname: Jia
authors.forename: Fei-Fei
authors.initials: FF
authors.lastname: Fan
authors.forename: Xing-Ya
authors.initials: XY
authors.lastname: Li
mesh_terms: D000071443:12E7 Antigen; D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D001932:Brain Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D015815:Cell Adhesion Molecules / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D018242:Neuroectodermal Tumors, Primitive / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D018241:Neuroectodermal Tumors, Primitive, Peripheral / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D010386:Pelvic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D016016:Proportional Hazards Models; D051789:Proto-Oncogene Protein c-fli-1 / Q000378:metabolism*; D009418:S100 Proteins / Q000378:metabolism; D015996:Survival Rate; D016708:Synaptophysin / Q000378:metabolism; D014746:Vimentin / Q000378:metabolism; D055815:Young Adult
chemical_list: D000071443:12E7 Antigen; D015703:Antigens, CD; C061828:CD99 protein, human; D015815:Cell Adhesion Molecules; C078433:FLI1 protein, human; D051789:Proto-Oncogene Protein c-fli-1; D009418:S100 Proteins; D016708:Synaptophysin; D014746:Vimentin; D010751:Phosphopyruvate Hydratase